FeesSafety
Pluang+

Cantor Fitzgerald raises price targets on Eli Lilly, AbbVie, Merck, and Pfizer amid mixed growth outlooks.

Analyst Insights
09 Oct 2026, 15:00 WIB
24/7 Wall Street
View Source
Bullish
Cantor Fitzgerald raises price targets on Eli Lilly, AbbVie, Merck, and Pfizer amid mixed growth outlooks.

Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronger conviction, whereas Merck and Pfizer were rated Neutral despite raised targets. The firm highlighted differing growth prospects, with Lilly and AbbVie showing robust revenue growth and promising drug momentum, while Merck and Pfizer face more uncertainty and upcoming catalysts. Investors should watch clinical results and 2027 earnings revisions for clearer direction.

As of Oct 09, 2026 18:51 WIB, Eli Lilly trades at USD 1,168.00 with a slight 1-day decline of 0.16% on Pluang. AbbVie shows a modest 0.20% gain, priced at USD 272.97, with a strong buy interest of 78% among Pluang users. Merck, meanwhile, faces heavier selling pressure with 82% sell activity despite a small 0.13% price increase to USD 142.58.

More News (LLY)

Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Eli Lilly leads obesity drug market with strong sales and promising pipeline, securing its top position.

Eli Lilly dominates the obesity drug market with its approved treatments Zepbound and Foundayo, showing strong sales growth—Zepbound's revenue rose 49% to $5.4 billion in Q3 2026. The company’s pipeline includes promising candidates like retatrutide ...

Market News
Bullish
2 hours ago
Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly leads obesity drug market with strong sales and promising pipeline despite rising competition.

Eli Lilly remains a leader in the obesity drug market with its approved products Zepbound and Foundayo showing strong sales growth. New pipeline candidates like retatrutide and EloraTZP have demonstrated greater weight loss in trials, positioning the...

Market News
Bullish
7 hours ago
Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly's weight loss drugs drive 39% revenue surge, fueling strong growth outlook.

Eli Lilly has seen its revenue soar thanks to its dominance in the weight loss drug market, with products like Mounjaro and Zepbound contributing to a 39% revenue increase to over $24 billion recently. The company leads in GLP-1 drugs, which regulate...

Market News
Bullish
16 hours ago
Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's Zepbound shows strong weight loss results in adolescents, opening a $6.5B market opportunity.

Eli Lilly's weight loss drug Zepbound demonstrated significant effectiveness in a clinical trial involving adolescents aged 12 to 17, with participants losing an average of 40 pounds and showing improved health markers. This success could lead to lab...

Company Fundamentals
Bullish
1 day ago
Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk rebounds with successful GLP-1 pill launch, boosting dividend yield amid competitive weight-loss market.

Novo Nordisk lost its lead in the GLP-1 weight-loss shot market to Eli Lilly due to supply issues but has rebounded strongly with its new GLP-1 pill, which captured 80% of new oral treatment patients in Q3 2026. The company is shifting to a volume-dr...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App